* Pliant Therapeutics Inc PLRX.OQ reported a quarterly
adjusted
loss of 78 cents per share for the quarter ended in March,
lower than the same quarter last year, when the company reported
EPS of -67 cents. The mean expectation of thirteen analysts for
the quarter was for a loss of 77 cents per share. Wall Street
expected results to range from -83 cents to -66 cents per share.
* Reported revenue was zero; analysts expected $464.50
thousand.
* Pliant Therapeutics Inc's reported EPS for the quarter was
a
loss of 78 cents.
* The company reported a quarterly loss of $46.96 million.
* Pliant Therapeutics Inc shares had fallen by 7.4% this
quarter and lost 23.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 6.3%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"
Wall Street's median 12-month price target for Pliant
Therapeutics Inc is $41.00
This summary was machine generated from LSEG data May 7 at 12:20
p.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.77 -0.78 Missed
Dec. 31 2023 -0.81 -0.69 Beat
Sep. 30 2023 -0.77 -0.70 Beat
Jun. 30 2023 -0.71 -0.70 Beat